Strategy and Status of Neoadjuvant Therapy for HER2-positive Breast Cancer
10.3971/j.issn.1000-8578.2024.23.0942
- VernacularTitle:HER2阳性乳腺癌新辅助治疗策略和现状
- Author:
Yunjiang LIU
1
;
Chao YANG
Author Information
1. The Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
- Publication Type:Research Article
- Keywords:
HER2-positive breast cancer;
Neoadjuvant therapy;
pCR;
Trastuzumab;
Pertuzumab
- From:
Cancer Research on Prevention and Treatment
2024;51(1):12-15
- CountryChina
- Language:Chinese
-
Abstract:
Neoadjuvant therapy is a preoperative systemic treatment for patients with breast cancer. This therapy has greatly improved the clinical outcomes of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which is associated with poor prognosis. Currently, dual anti-HER2 antibodies, including trastuzumab and pertuzumab, combined with non-anthracycline chemotherapy is one of the standard regimens to achieve high pathologic complete response rate and satisfactory efficacy. The combination of trastuzumab with tyrosine kinase inhibitors, antibody-drug conjugate drugs, or immunotherapy combined with target therapy, under the indications of reasonable biomarkers, is effective for HER2-positive breast cancer. In this article, we briefly reviewed neoadjuvant therapy in the dual-targeting therapy era and discussed its future perspectives.
